- Amprenavir
drugbox
IUPAC_name = tetrahydrofuran-3-yl [3- [(4-aminophenyl)sulfonyl- (2-methylpropyl) amino] -1-benzyl-2- hydroxy-propyl] aminomethanoate
CAS_number = 161814-49-9
ATC_prefix = J05
ATC_suffix = AE05
ATC_supplemental =
PubChem = 65016
DrugBank = APRD00605
C=25 | H=35 | N=3 | O=6 | S=1
molecular_weight = 505.628 g/mol
bioavailability =
protein_bound = 90%
metabolism = hepatic
excretion = <3% renal
elimination_half-life = 7.1-10.6 hours
licence_EU = Agenerase
licence_US = Amprenavir
pregnancy_US = C
pregnancy_category =
legal_status =
routes_of_administration = oralAmprenavir (Agenerase,
GlaxoSmithKline ) is a protease inhibitor used to treatHIV infection. It was approved by theFood and Drug Administration onApril 15 ,1999 , for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200mg, delivered in eight very large gel capsules.Production of amprenavir was discontinued by the manufacturer
December 31 ,2004 ; aprodrug version (fosamprenavir ) is available.See also
*
Fosamprenavir , a prodrug of amprenavir
Wikimedia Foundation. 2010.